Before any FDA reviewer evaluates whether your device is substantially equivalent to a predicate, a separate reviewer runs your 510(k) against a fixed administrative checklist and decides, within 15 calendar days, whether the submission is accepted for review at all. That is FDA's Refuse to Accept (RTA) Policy for 510(k)s, finalized April 21, 2022 — and it has nothing to do with whether the device works. It has to do with whether the submission is complete enough for a substantive reviewer to start.

What the checklist actually tests

RTA is not a quality review and not a merit review. It is a gate that asks one question, item by item: is each element the checklist requires present in the submission, or has the sponsor explained why it does not apply? FDA's acceptance reviewer works through the applicable appendix and, where an item appears to be missing, considers whether the sponsor provided a rationale for the omission rather than simply leaving a gap. That distinction matters for how a submission should be built: a missing section is a defect, but a section deliberately scoped out with a stated reason is not automatically one. Confusing the two — filing something incomplete and hoping a reviewer infers the reasoning — is where sponsors lose the 15-day window they didn't need to lose.

15 days
FDA's target window for an RTA accept-or-refuse decision, under the April 2022 guidance.
3
Separate checklist appendices — Traditional, Abbreviated, and Special 510(k) — each with its own item set.
2022
The year FDA finalized the current RTA guidance, superseding the September 2019 version.

Which checklist applies

The RTA guidance does not run one checklist against every 510(k). A Traditional 510(k) and an Abbreviated 510(k) are assessed against a shared set of items organized into roughly a dozen categories — covering administrative elements, device description, substantial equivalence discussion, and performance data, among others. A Special 510(k), reserved for well-defined device modifications, runs against a shorter checklist built around a narrower set of categories, reflecting the more limited scope FDA expects a Special 510(k) to cover in the first place. Picking the wrong appendix to self-check against — treating a Special 510(k) as if it needs the full Traditional item set, or the reverse — wastes the self-check before it starts.

  • Traditional 510(k). The full checklist, covering administrative completeness through substantial equivalence and performance data.
  • Abbreviated 510(k). Assessed against the same category structure as Traditional, built around reliance on FDA-recognized consensus standards, guidance documents, or special controls in place of full comparative testing.
  • Special 510(k). A narrower checklist built for well-defined modifications to a sponsor's own previously cleared device, where the change is supported by the sponsor's existing design-control documentation rather than a new comparative study.
RTA doesn't ask whether your device is good. It asks whether your submission is organized well enough for someone else to find out. Why a complete-but-weak submission clears RTA and an incomplete-but-strong one doesn't

Not the same gate as drug-side Refuse to File

RTA is easy to conflate with FDA's Refuse to File determination for NDAs and BLAs, and the two are built on different authority for different submission types entirely. Refuse to File runs under 21 CFR 314.101(d) and 601.2(a) for drug and biologic marketing applications, with its own 60-day clock and its own completeness standard tied to the statutory and regulatory elements those applications require. RTA runs under FDA's device-side acceptance review policy for 510(k)s specifically, on a 15-day clock, against the checklist appendices described above. A combination-product or device-and-drug program working both pathways needs both gates mapped separately — passing one says nothing about the other.

Build the self-check in before FDA runs it for you

The guidance itself points toward the fix: where a sponsor's submission departs from a checklist item, FDA's reviewer looks for a stated rationale. That means a sponsor can run the applicable checklist against its own draft before filing, document a justification for any item that genuinely does not apply, and include that self-assessment with the submission. Where a checklist item turns on a genuine judgment call — not an obvious omission, but a question about how FDA will read a particular element — raising it through a Q-Submission ahead of filing is the lower-risk way to find out than discovering it inside the 15-day acceptance window, where there is no mechanism to ask a clarifying question before the clock runs out.

A pre-submission RTA sequence to run now
  1. Confirm the submission type first. Traditional, Abbreviated, or Special — each reaches a different checklist appendix.
  2. Run the applicable checklist against your own draft. Item by item, before the submission is considered final.
  3. Document a rationale for every deliberate omission. A stated reason is a different finding than a silent gap.
  4. Raise genuine judgment calls through a Q-Submission. Ahead of filing, not inside the 15-day acceptance window.
  5. File the completed checklist with the submission. It gives FDA's acceptance reviewer the completeness case already made.

None of this is exotic once the checklist is treated as a design input rather than a post-hoc audit. What costs sponsors the 15-day window is building a 510(k) first and checking it against the RTA appendix afterward, instead of scoping the submission against the right checklist from the start. If your 510(k) program's acceptance-review track record has been inconsistent, that is where to start; our 510(k) clearance strategy work exists for exactly this gap.

Frequently asked questions

What does FDA's Refuse to Accept policy actually test?

Administrative completeness, not substantive merit. FDA's acceptance reviewer checks a 510(k) against a fixed checklist — is each required element present, or is a justification provided for leaving it out — before the submission ever reaches a reviewer evaluating the underlying science or substantial equivalence. A complete-but-weak submission passes RTA; an incomplete-but-strong one does not.

How long does FDA have to make an RTA decision?

FDA's current Refuse to Accept Policy for 510(k)s guidance, finalized April 21, 2022, targets a decision within 15 calendar days of receipt — whether the submission is accepted for substantive review or refused for identified deficiencies. That clock runs before, and separately from, the substantive review timeline that follows acceptance.

What happens if a 510(k) is refused under RTA?

FDA returns a copy of the checklist marking the items it considers missing or unjustified. Resubmission is generally limited to addressing those specific items rather than refiling the entire submission — which is why a sponsor's own pre-submission run of the same checklist is worth doing before FDA runs it first.

Sources & further reading

  1. FDA. Refuse to Accept Policy for 510(k)s — Guidance for Industry and Food and Drug Administration Staff (April 21, 2022). fda.gov
  2. HHS-hosted mirror. Refuse to Accept Policy for 510(k)s — Guidance for Industry and FDA Staff. hhs.gov

This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current FDA RTA checklist requirements with FDA or qualified counsel before filing.